A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee
Latest Information Update: 22 Feb 2021
At a glance
- Drugs Celecoxib (Primary) ; Ibuprofen
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Pfizer; Viatris
- 11 Dec 2017 New trial record
- 01 Dec 2017 Results (n=441) of analysis comparing safety and efficacy of celecoxib with placebo in Asian and Non Asian population using patient data from A3191052 and A3191063 trials published in the Pain and Therapy